You are not logged in
You need to be a member to print this page.
Sign up for free membership, or log in.
Find out more about our membership benefits
VIEW TAGS
Articles tagged ‘type 2 diabetes’
March 2012
Br J Cardiol 2012;19:26–9
Drugs for diabetes: part 8 SGLT2 inhibitors
SGLT2 inhibitors are a new class of oral drugs for the treatment of type 2 diabetes mellitus currently in phase III studies. They inhibit glucose
August 2011
Br J Cardiol 2011;18:167–69
Drugs for diabetes: part 6 GLP-1 receptor agonists
The glucagon-like peptide-1 (GLP-1) receptor agonists are a new class of injected drugs for the treatment of type 2 diabetes. They mimic the action of
June 2011
Br J Cardiol 2011;18:130–2
Drugs for diabetes: part 5 DPP-4 inhibitors
The dipeptidyl peptidase-4 (DPP-4) inhibitors are a new class of oral drugs for the treatment of type 2 diabetes. They inhibit the breakdown of glucagon-like
April 2011
Br J Cardiol 2011;18:78−81
Drugs for diabetes: part 4 acarbose
Acarbose is an alpha-glucosidase inhibitor acting in the gastrointestinal tract producing modest reductions in postprandial hyperglycaemia, with negligible risk of hypoglycaemia and weight gain. In
November 2010
Br J Cardiol 2010;17:279–82
Drugs for diabetes: part 2 sulphonylureas
Sulphonylureas are well established in the treatment of type 2 diabetes mellitus. They are effective in improving glycaemic control and preventing microvascular complications. Side effects
September 2010
Br J Cardiol 2010;17:231–4
Drugs for diabetes: part 1 metformin
Metformin is one of the oldest oral treatments to reduce hyperglycaemia in people with diabetes. Gastrointestinal side effects are common, and metformin should be used
November 2009
Br J Cardiol 2009;16:269-71
CHD risk is being overestimated in diabetes
The Framingham and UKPDS (United Kingdom Prospective Diabetes Study) risk equations overestimate the probability of cardiovascular events in people with type 2 diabetes, according to
July 2009
Br J Cardiol 2009;16:163-6
New NICE guidelines on new treatments for type 2 diabetes
The National Institute for Health and Clinical Excellence (NICE) has issued a new guidance on the use of several newer agents for blood glucose control
November 2008
Br J Cardiol 2008;15:301
News from the EASD
This year’s European Association for the Study of Diabetes meeting took place in Rome, Italy. Rhonda Siddall reports on the highlights of the meeting, which